Appl. No.: 10/820,298 Art Unit: 1612

Reply to Office Action of 09/17/2009

Patent 17224CON (AP)

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A method for treating proliferative skin diseases comprising the administration of an effective amount of <u>about 0.1% to about 2%</u> 1.0 % tazarotene gel and an effective amount of a corticosteroid, wherein said corticosteroid is <u>alclometasone</u> <u>dipropionate and/or betamethasone valerate</u> <u>sSelected from the group consisting of fluocinolone acetonide, mometasone furoate, fluocinonide, diflorasone diacetate, fluticasone propionate, betamethasone dipropionate, clobetasol propionate, and betamethasone valerate.</u>

2-5. (Cancelled)

6. (Currently Amended) A method for treating psoriasis in a human subject by topically applying to the psoriatic skin of said subject an effective amount of <u>about 0.1% to about 2% 1.0 %</u> tazarotene and an effective amount of a corticosteroid <u>wherein said corticosteroid is</u> alclometasone dipropionate and/or betamethasone valerate.

7-10. (Cancelled)

- 11. (Currently Amended) The method of claim <u>6</u> [[10]] wherein tazarotene is administered once daily in the evening and the corticosteroid is administered once daily in the morning.
- 12. (Currently Amended) The method of Claim 6 wherein the 1.0 % tazarotene is applied as a 1.0 % gel.
- 13. (Currently Amended) The method of Claim 6 wherein the 1.0 % tazarotene is applied as a 1.0 % cream.
- 14. (Canceled)